Abstract:

Objective To investigate the feasibility and safety of low⁃dose ticagrelor in acute coronary syn⁃ drome with percutaneous coronary intervention after 12months. Methods The acute coronary syndrome patients who underwent PCI in our hospital after 1 year from January 2017 to June 2019 were enrolled and randomly divided into three groups according to different antiplatelet strategies：Aspirin group（100 mg，once a day），Ticagrelor group（90mg twice daily）and Low⁃dose ticagrelor group（60 mg，twice daily）. At a follow⁃up of 24 months，the Major Adverse Cardiovascular Events（MACCE）and all bleeding events were compared among the three groups， and platelet aggregation rates were measured. Results During the follow⁃up，there was no statistical significance in the incidence of MACCE among 3 groups（P > 0.05）. Compared with the Aspirin group and Ticagrelor group， the Low⁃dose ticagrelor group had a decreasing trend of BARC1 hemorrhage，and the difference was statistically significant（P = 0.002）. There was no statistical significance in the risk of bleeding above BARC1 among the three groups（P > 0.05）. There was no statistical significance in platelet aggregation rate between 2 groups at each follow⁃ up time（P > 0.05）. Conclusions After 1year，in the selection of antiplatelet agents in acute coronary syndrome with PCI，low⁃dose ticagrelor can effectively reduce the incidence of bleeding events without affecting the antiplatelet aggregation effect.

Key words:

coronary heart disease, percutaneous coronary intervention, low dose, Ticagrelor